2BBBullish & Bearish
Mesoblast Ltd (MESO) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 46 out of 100.
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.
Mesoblast Ltd’s current 2BB score is 46 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 50 | Moderate |
| Momentum | 44 | Stable |
| Financial strength | 35 | Weak |
| Quality | 76 | Strong |
| Risk | 35 | Low |
| CEO | Silviu Itescu |
| Founded | 2004 |
| Employees | 108 |
| 52-week range | $13.05 – $21.49 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-24 | — | -0.0232 | — | $69.69M |
| 2026-08-26 | — | -0.1061 | — | $66.66M |